Over the past decade anti-HIV drugs have dramatically improved the prognosis for HIV infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the anti-HIV drug “maraviroc” from being more widely used in anti-HIV therapy regimens is that the pre-treatment in silico tests to determine virus susceptibility to maraviroc have been developed primarily for HIV subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of highly accurate in silico tests for all of the major HIV subtypes, namely subtypes A, B, C, D, CRF01_AE and CRF02_AG, which together account for 95% of HIV-1 infections worldwide. PhenoSeq will inform the appropriate use of maraviroc in regions of the world where non-B HIV predominates, which are burdened the most by the HIV-1 pandemic.

The PhenoSeq platform comprises a suite of subtype specific V3 sequence-based genotypic tropism tests, designed specifically to predict the coreceptor usage of HIV-1 subtype A, B, C, D, CRF01_AE and CRF02_AG viruses.

To access PhenoSeq click here.

Contact Details

For any general enquiries relating to this facility, please contact:

Doctor Gary Peter Jamieson

Facilities Officer